Antagonists of growth hormone-releasing hormone inhibit the growth of U- 87MG human glioblastoma in nude mice

Neoplasia

Volumn 2, Issue 3, 2000, Pages 242-250

  Kiaris, Hippokratis ^a   Schally, Andrew V ^a,b   Varga, Jozsef L ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Brain tumors; Cancer therapy; GH RH; IGF; IGF receptor

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; JV 136; MESSENGER RNA; MZ 5 156; SOMATOMEDIN B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0034082386     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900074     Document Type: Article

References (31)

1. Schoenberg BS (1983). In Oncology of the Nervous System. MD Walker (Ed). Nijhoff, Boston. pp. 1-30.
2. Hochberg F, and Pruitt A (1987). In Harrison's Principles of Internal Medicine (11th ed). E Braunwals, KJ Isselbacher, RG Petersdorf, JD Wilson, JD Martin, S Fauci (Eds). McGraw-Hill, New York. pp. 1968-1980.
3. Fine HA, Dear KBG, Loeffler JS, Black PM, and Canellos GP (1993). Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (Philadelphia) 8, 2585-2597.
4. Antoniades HN, Galanopoulos T, Neville Golden J, and Maxwell M (1992). Expression of insulin-like growth factors I and II and their receptor mRNA in primary human astrocytomas and meningiomas: in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 50, 215-222.
5. Glick RP, Gettleman R, Patel K, Lakshman R, and Tsibris JC (1989). Insulin and insulin-like growth factor I in brain tumors: binding and in vitro effects. Neurosurgery 24, 791-797.
6. Glick RP, Unterman TG, and Hollis R (1991). Radioimmunoassay of insulin-like growth factors in cyst fluid of central nervous system tumors. J Neurosurg 74, 972-978.
7. Merrill MJ, and Edwards NA (1990). Insulin-like growth factor-I receptors in human glial tumors. J Clin Endocrinol Metab 71, 199-209.
8. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, and Armatis P (1995). Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst 87, 1787-1794.
9. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P, and Vadillo-Buenfil M (1997). Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 75, 1585-1592.
10. Lamharzi N, Schally AV, Koppan M, and Groot K (1998). Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 95, 8864-8868.
11. Kahan Z, Schally AV, Varga JL, and Rekasi Z (1999). Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice and inhibit the expression of mRNA for IGF-I in tumors. Breast Cancer Res Treat, In press.
12. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, and Halmos G (1997). Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caci-I renal adenocarcinoma. Proc Natl Acad Sci USA 94, 5810-5813.
13. Pinski J, Schally AV, Jungwirth A, Groot K, Halmos G, Armatis P, Zarandi M, and Vadillo-Buenfil M (1996). Inhibition of growth of small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int J Oncol 9, 1099-1105.
14. Schally AV, Kovacs M, Toth K, and Comaru-Schally AM (1998). Antagonistic Analogs of Growth Hormone-Releasing Hormone (GH-RH): Endocrine and Oncological Studies. In Growth Hormone Secretagogues. BB Bercu, RF Walker (Eds). Marcel Dekker, New York. pp. 145-162.
15. Csernus VJ, Schally AV, Kiaris H, and Armatis P (1999). Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 96, 3098-3103.
16. Kiaris H, and Schally AV (1999). Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci U S A 96, 226-231.
17. Zarandi M, Kovacs M, Horvath JE, Toth K, Halmos G, Groot K, Nagy A, Kele Z, and Schally AV (1997). Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides 18, 423-430.
18. Varga JL, Schally AV, Csemus VJ, Zarandi M, Halmos G, Groot K, and Rekasi Z (1999). Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA 96, 692-697.
19. Bernhardt G, Reile H, Birnbock H, Sprub T, and Schonenberger H (1992). Standarized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol 118, 35-43.
20. Redding TW, and Schally AV (1983). Inhibition of growth of transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 80, 1078-1082.
21. Pinski J, Schally AV, Halmos G, Szepeshazi K, and Groot K (1994). Somatostatin analogues and bombesin/gastrin releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 54, 5895-5901.
22. Voutilainen R, Franks S, Mason HD, and Martikainen H (1996). Expression of insulin-like growth factor (IGF), IGF-binding protein, and IGF receptor messenger ribonucleic acids in normal and polycystic ovaries. J Clin Endocrinol Metab 81, 1003-1008.
23. Kahan Z, Arencibia JM, Csemus VJ, Groot K, Kineman RD, Robinson WR, and Schally AV (1999). Expression of growth hormone-releasing hormone (GH-RH) messenger ribonucleic acid and the presence of biologically active GH-RH in human breast endometrial, and ovarian cancers. J Clin Endocrinol Metab 84, 582-589.
24. Steel RGD, and Torrie J (1976). In Principles and Proccedures of Statistics. McGraw Hill, New York. p. 114.
25. Nissley SP, and Lopeszinsky W (1991). IGF receptors. Growth Factors 5, 29-43.
26. Resnicoff M, Tjuvajev J, Rotman HL, Abraham D, Curtis M, Aiken R, and Baserga R (1996). Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor mRNA. J Exp Ther Oncol 1, 385-389.
27. Rininsland F, Johnson TR, Chernicky CL, Schulze E, Burfeind P, and Ilan J (1997). Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA 94, 5854-5859.
28. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, and Jirtle RL (1995). Frequent loss of heterozygosity on 6q at the mannose-6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10, 1725-1729.
29. De Souza AT, Hankins GR, Washington MK, Orton TC, and Jirtle RL (1995). M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11, 447-449.
30. Kornfeld S (1992). Structure and function of the mannose-6-phosphate/insulin-like growth factor II receptors. Annu Rev Biochem 61, 307-330.
31. Souza RF, Wang S, Thakar M et al. (1999). Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 18, 4063-4068.